Cassava Appears Overvalued And Lacks Rigorous Alzheimer's Data Seeking Alpha, 06 Apr 2023 Summary Cassava Sciences' Phase 2 open-label safety study of simufilam shows mixed outcomes for treating Alzheimer's disease.